Establishment of National Diagnostic Reference Levels 2025 for nuclear medicine in Japan

IF 2.5 4区 医学 Q2 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING
Koichiro Abe, Shingo Baba, Reo Etani, Takahiro Fujimto, Makoto Hosono, Takashi Iimori, Anri Inaki, Masanobu Ishiguro, Noriaki Miyaji, Atsutaka Okizaki, Takeshi Sasaki, Hiroyuki Tsushima, Hiroshi Watanabe, Masanori Watanabe, Nobuhiro Yada
{"title":"Establishment of National Diagnostic Reference Levels 2025 for nuclear medicine in Japan","authors":"Koichiro Abe,&nbsp;Shingo Baba,&nbsp;Reo Etani,&nbsp;Takahiro Fujimto,&nbsp;Makoto Hosono,&nbsp;Takashi Iimori,&nbsp;Anri Inaki,&nbsp;Masanobu Ishiguro,&nbsp;Noriaki Miyaji,&nbsp;Atsutaka Okizaki,&nbsp;Takeshi Sasaki,&nbsp;Hiroyuki Tsushima,&nbsp;Hiroshi Watanabe,&nbsp;Masanori Watanabe,&nbsp;Nobuhiro Yada","doi":"10.1007/s12149-025-02102-y","DOIUrl":null,"url":null,"abstract":"<div><p>Diagnostic reference levels (DRLs) are practical benchmarks for optimizing patient radiation exposure in medical imaging. In Japan, national DRLs, including those for nuclear medicine together and other radiological procedures, were first established in 2015 and revised in 2020. In this study, we revised the DRL values of nuclear medicine for the establishment of DRLs2025, based on data collected from institutions nationwide throughout Japan. Data were collected via an online survey from facilities performing nuclear medicine procedures, including SPECT, PET, and hybrid CT imaging. Information on dose activity of the administered radiopharmaceuticals and CT parameters (CTDIvol and DLP) were collected. DRL values were determined through analysis of the submitted data, supplemented by panel discussions among experts taking into account the clinical appropriateness of the values and various technological factors. Overall, the newly established DRLs2025 demonstrated a decreasing trend in administered radiopharmaceutical activities, CTDIvol, and DLP compared with the previous surveys. This trend reflects ongoing efforts toward the optimization of radiation exposure and radiopharmaceutical dose reduction, likely driven by the introduction of image reconstruction methods based on newer technologies. However, substantial interfacility variations were observed, particularly in the CT parameters, suggesting disparities in equipment, imaging protocols, and the balance between image quality and radiation dose. The establishment of DRLs2025 underscores continued progress in optimizing radiation exposure in nuclear medicine practice in Japan. Although issues regarding data variability and quality remain, DRLs continue to be a key tool in radiation protection and quality assurance. Ongoing efforts to improve data collection systems and to align procedures with international standards are essential for the future refinement of DRLs.</p></div>","PeriodicalId":8007,"journal":{"name":"Annals of Nuclear Medicine","volume":"39 10","pages":"1027 - 1036"},"PeriodicalIF":2.5000,"publicationDate":"2025-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s12149-025-02102-y.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Nuclear Medicine","FirstCategoryId":"3","ListUrlMain":"https://link.springer.com/article/10.1007/s12149-025-02102-y","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
引用次数: 0

Abstract

Diagnostic reference levels (DRLs) are practical benchmarks for optimizing patient radiation exposure in medical imaging. In Japan, national DRLs, including those for nuclear medicine together and other radiological procedures, were first established in 2015 and revised in 2020. In this study, we revised the DRL values of nuclear medicine for the establishment of DRLs2025, based on data collected from institutions nationwide throughout Japan. Data were collected via an online survey from facilities performing nuclear medicine procedures, including SPECT, PET, and hybrid CT imaging. Information on dose activity of the administered radiopharmaceuticals and CT parameters (CTDIvol and DLP) were collected. DRL values were determined through analysis of the submitted data, supplemented by panel discussions among experts taking into account the clinical appropriateness of the values and various technological factors. Overall, the newly established DRLs2025 demonstrated a decreasing trend in administered radiopharmaceutical activities, CTDIvol, and DLP compared with the previous surveys. This trend reflects ongoing efforts toward the optimization of radiation exposure and radiopharmaceutical dose reduction, likely driven by the introduction of image reconstruction methods based on newer technologies. However, substantial interfacility variations were observed, particularly in the CT parameters, suggesting disparities in equipment, imaging protocols, and the balance between image quality and radiation dose. The establishment of DRLs2025 underscores continued progress in optimizing radiation exposure in nuclear medicine practice in Japan. Although issues regarding data variability and quality remain, DRLs continue to be a key tool in radiation protection and quality assurance. Ongoing efforts to improve data collection systems and to align procedures with international standards are essential for the future refinement of DRLs.

日本核医学国家诊断参考水平2025的建立。
诊断参考水平(drl)是优化医学成像中患者辐射暴露的实用基准。在日本,包括核医学和其他放射程序在内的国家drl于2015年首次建立,并于2020年进行了修订。在本研究中,我们根据日本全国各机构收集的数据,修订核医学的DRL值,以建立DRLs2025。数据通过在线调查从执行核医学程序的设施收集,包括SPECT, PET和混合CT成像。收集了放射性药物的剂量活性信息和CT参数(CTDIvol和DLP)。DRL值是通过分析提交的数据确定的,辅以专家小组讨论,考虑到这些值的临床适宜性和各种技术因素。总体而言,与之前的调查相比,新建立的DRLs2025在给药放射性药物活性、CTDIvol和DLP方面显示出下降趋势。这一趋势反映了对优化辐射暴露和减少放射性药物剂量的持续努力,可能是由基于新技术的图像重建方法的引入所推动的。然而,观察到大量的设施间差异,特别是在CT参数方面,表明设备,成像方案以及图像质量和辐射剂量之间的平衡存在差异。DRLs2025的建立强调了日本核医学实践中在优化辐射暴露方面的持续进展。虽然关于数据变异性和质量的问题仍然存在,但drl仍然是辐射防护和质量保证的关键工具。正在进行的改进数据收集系统和使程序与国际标准保持一致的努力,对于今后改进drl至关重要。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Annals of Nuclear Medicine
Annals of Nuclear Medicine 医学-核医学
CiteScore
4.90
自引率
7.70%
发文量
111
审稿时长
4-8 weeks
期刊介绍: Annals of Nuclear Medicine is an official journal of the Japanese Society of Nuclear Medicine. It develops the appropriate application of radioactive substances and stable nuclides in the field of medicine. The journal promotes the exchange of ideas and information and research in nuclear medicine and includes the medical application of radionuclides and related subjects. It presents original articles, short communications, reviews and letters to the editor.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信